BioStock Studio: SynAct Pharma comments on the promising study results in RA

SynAct Pharma has announced top-line results from BEGIN, a phase IIa study of AP1189 in rheumatoid arthritis.

The company’s CEO Jeppe Øvlesen and CMO Anders Dyhr Toft came to BioStock’s studio to talk about the study results and the plans going forward.

See the full interview with SynAct Pharma’s CEO Jeppe Øvlesen och CMO Anders Dyhr Toft below.

Notiser